The goal of this clinical trial (Phase II) is to evaluate the efficacy and safety of neoadjuvant Adebrelimab combined with chemoradiation in patients with locally advanced thymic carcinoma. The main questions it aims to answer are:
* Is neoadjuvant therapy with Adebrelimab plus chemoradiation effective?
* Is this combination treatment safe and tolerable in this patient population?
Participants will:
* Receive 2-4 cycles of neoadjuvant Adebrelimab combined with a platinum-based chemotherapy regimen (such as carboplatin plus paclitaxel) and concurrent radiotherapy prior to surgery.
* Undergo re-staging imaging to assess tumor response and determine surgical candidacy.
* Undergo surgical resection if the tumor is resectable after neoadjuvant treatment.
* Receive adjuvant Adebrelimab therapy for up to one year following surgery.
* Undergo regular follow-up visits for safety monitoring and survival assessment.